Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations

Abstract

This study provides Class II evidence that in individuals with CKD stage 3 (especially stage 3b) or higher, p-tau217 concentrations are increased, with a greater increase in amyloid-PET-negative individuals.